Aroa Biosurgery Ltd (AU:ARX) has released an update.
Aroa Biosurgery Limited, a leader in soft tissue regeneration, has reported substantial growth and confidence in their AROA ECM technology, with over six million devices used in patient treatments and supported by 83 peer-reviewed clinical publications. The company has a strong market presence, with access to over 95% of US hospitals and consistent sales growth, notably a 73% increase in Myriad product sales, despite a temporary reduction in shipments to TELA Bio. With ambitious financial targets and a skilled workforce, Aroa Biosurgery is focused on expanding its market share and building a highly valuable business in the multi-billion dollar soft tissue regeneration market.
For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.
